ZMYND11 and prostate carcinoma: Our results revealed a clear and frequent downregulation of ZMYND11 in non-epithelial cancers (brain, mesothelioma) and in multiple epithelial cancer types (cervix, colorectal, esophagus, stomach, pancreas, prostate), with a particularly significant reduction observed in prostate cancer (Fig. 1a).